FinancialBuzz.com Exclusive Interview With CEL-SCI (NYSE: CVM) CEO Geert Kersten From the Floor of the NYSE

NEW YORK, Feb. 23, 2015 /PRNewswire/ — www.FinancialBuzz.com, a leader in the digital financial news space, video production and integration of social media, today announces an exclusive HD video interview with CEL-SCI Corp. (NYSE: CVM) Chief Executive Officer, Geert Kersten from the floor of the New York Stock Exchange (NYSE).

Mr. Kersten provides the latest insight and why he is very excited about CEL-SCI’s future and touches on multiple potential catalyst events coming up in 2015. Why is Mr. Kersten so bullish? Have insiders increased their positions? What is currently happening with the company’s lead investigational therapy Multikine (Leukocyte Interleukin, Injection) study in a pivotal Phase III clinical trial against head and neck cancer?

Hear it first and directly from the CEO of CEL-SCI Corp. Just two months into 2015, shares of CEL-SCI Corporation (NYSE MKT: CVM) have surged as high as 83% (based on January 2, 2015 low of $.59 and February 19, 2015 high of $1.08).

Click here to view full HD quality video interview https://www.youtube.com/watch?v=FoLpbuZnZEM

About Financial Buzz Media      

FinancialBuzz.com, a leading informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

Financial Buzz Media provides credible branding, marketing and advertising through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, TV Broadcasting, and Financial Publications. In a public financial market that requires extensive transparency and disclosures, Financial Buzz Media provides one of the most internationally credible media outlets by reporting live from various locations; The New York Stock Exchange, NASDAQ Exchange and Hong Kong Exchange.

For “the latest buzz in financial news” every day, please visit www.FinancialBuzz.com.

About CEL-SCI Corporation

CEL-SCI’s work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. CEL-SCI believes that the best way may be to activate the immune system of patients before they have received surgery, radiation and/or chemotherapy. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is currently being studied in a pivotal Phase III clinical trial against head and neck cancer. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with Multikine treatment regimen as compared to subjects treated with current standard of care only is satisfied, the study results will be used to support applications which will be submitted to regulatory agencies in order to receive from these agencies commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine which are being investigated include cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Navy under a CRADA.

CEL-SCI is also developing its LEAPS technology for the treatment of pandemic influenza and as a potential therapeutic vaccine against rheumatoid arthritis. CEL-SCI received a Phase I SBIR Grant from the National Institutes of Health to develop LEAPS as a potential treatment for rheumatoid arthritis with researchers from Rush University Medical Center in Chicago, Illinois. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

Media Contact:

Henry Wong, +1-(877)-601-1879 or Henry@financialbuzz.com


Leave a Comment